Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemiaSophie Park, Didier Bouscary, Nicolas Chapuis et al.|Haematologica|2009Cited by 316
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemiaLise Willems, Didier Bouscary, Alain Schmitt et al.|Blood|2013Cited by 286
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathwaysJérôme Tamburini, Didier Bouscary, Nicolas Chapuis et al.|Blood|2007Cited by 252
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translationAlexa S. Green, Jérôme Tamburini, Nicolas Chapuis et al.|Blood|2010Cited by 196
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AMLSophie Park, Didier Bouscary, Nicolas Chapuis et al.|Leukemia|2008Cited by 193